Senozam (senozam) 1 mg/ml Solution for Infusion
Prescription-only intravenous medicine administered in a supervised healthcare setting
Quick Facts About Senozam
Key Takeaways About Senozam
- Hospital-administered medicine: Senozam is given only by a healthcare professional via intravenous infusion and is not available for self-administration.
- Prescription only: Senozam cannot be purchased over the counter; a valid prescription and medical assessment are required before treatment.
- Strength: Senozam is supplied as a 1 mg/ml solution for infusion; the volume and total dose delivered are calculated individually for each patient.
- Individualized treatment: Indication, dose, infusion rate and monitoring depend on the patient's condition, organ function, age, weight and concurrent therapy.
- Report all medicines and allergies: Always inform the treating team about other medicines, supplements, past reactions, pregnancy status and chronic illnesses before an infusion is started.
What Is Senozam and What Is It Used For?
Senozam is a prescription-only medicine supplied as a 1 mg/ml clear solution for intravenous infusion. It contains senozam as its active ingredient and is administered by a healthcare professional in a hospital or clinic. The specific medical indication is determined by the prescribing physician in accordance with the authorized Summary of Product Characteristics (SmPC).
Senozam is a pharmaceutical product intended exclusively for intravenous administration. Unlike oral medications that a patient can take at home, Senozam must be delivered directly into a vein under the supervision of trained medical staff. This mode of administration allows for precise control over the dose that reaches the bloodstream, immediate titration of the infusion rate and rapid intervention should any untoward reaction occur during or shortly after the infusion.
The active substance in Senozam is senozam, formulated at a concentration of 1 mg per millilitre. This means that every 1 ml of the infusion solution contains 1 mg of the active ingredient. The total quantity infused during a single session is therefore directly proportional to the volume and the prescribed regimen. The physician calculates the appropriate dose for each patient based on factors such as indication, body weight, renal and hepatic function, age and clinical severity of the condition being treated.
Because Senozam is classified as a prescription-only medicine (often abbreviated as Rx), it can only be supplied by a pharmacy upon receipt of a valid prescription from a licensed prescriber and administered in a setting equipped to manage intravenous therapy. The decision to initiate treatment with Senozam is always preceded by a thorough clinical assessment, including medical history, physical examination, laboratory investigations and, where relevant, imaging studies.
Clinical Setting and Administration
Senozam is prepared and administered in a clinical environment that meets the safety standards for intravenous therapy. Typical settings include inpatient hospital wards, specialist outpatient clinics, infusion centres, day-care units and, in selected cases, home infusion services coordinated by a hospital team. In all of these settings, trained personnel are responsible for preparing the infusion, verifying patient identity, checking the product label, calculating the dose, setting the infusion rate and monitoring the patient during and after administration.
Before the infusion begins, the treating team will typically establish venous access through a peripheral cannula or, for longer courses of therapy, a central venous catheter. The infusion is controlled using an infusion pump or a gravity system according to the protocol specified in the SmPC and local institutional guidelines. Continuous clinical observation during the infusion is standard practice to detect any signs of an infusion reaction, circulatory disturbance or allergic event promptly.
Indication and Evidence Base
The authorized indications for Senozam, the expected therapeutic outcomes and the strength of the underlying evidence are described in detail in the current Summary of Product Characteristics approved by the relevant regulatory authority, such as the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA), and in national drug formularies such as the British National Formulary (BNF). Patients and caregivers are encouraged to consult these official sources, together with their treating physician, in order to understand the specific reason Senozam has been prescribed in their individual case.
This article provides general, educational information about Senozam as a prescription-only infusion medicine. It is not a substitute for the official Summary of Product Characteristics, the package leaflet or medical advice from your treating physician. Always consult these authoritative sources for indication-specific and patient-specific guidance.
What Should You Know Before Taking Senozam?
Before Senozam is administered, your healthcare team will review your full medical history, current medications, allergies and organ function. Senozam must not be given to anyone who is hypersensitive to the active ingredient or to any excipient. Special precautions apply to pregnant or breastfeeding patients, children, older adults and those with reduced kidney or liver function.
Because Senozam is a prescription-only intravenous therapy, the evaluation that takes place before treatment is at least as important as the infusion itself. The purpose of this pre-treatment assessment is to confirm that Senozam is the most appropriate option, to identify any factors that might increase the risk of adverse effects and to plan for safe administration and follow-up. The extent of the pre-treatment work-up depends on the indication, but it typically includes a detailed history, physical examination, blood tests and, if needed, imaging or other diagnostic investigations.
During this assessment, you should disclose everything that might be relevant, including prior adverse drug reactions, chronic diseases, recent hospitalisations, current and past medications, dietary supplements and lifestyle factors such as alcohol use. Providing complete information helps your healthcare team to individualize your treatment plan and to anticipate and manage potential risks.
Contraindications
Senozam must not be used in the following situations:
- Known hypersensitivity (allergy) to the active substance senozam or to any of the excipients listed in the formulation.
- Any condition for which the current Summary of Product Characteristics specifies that Senozam is contraindicated, such as certain severe organ dysfunctions, specific concomitant medications or particular clinical states.
If you think you may be allergic to Senozam or to any related substance, or if a previous infusion of this or a similar product caused symptoms such as rash, swelling, difficulty breathing or a drop in blood pressure, tell your doctor immediately so that alternative options can be considered.
Warnings and Precautions
Talk to your doctor or nurse before Senozam is administered if any of the following apply to you:
- Known allergies: Including allergies to foods, medicines, latex or preservatives, even if they are not directly related to Senozam.
- Chronic illnesses: Conditions affecting the heart, lungs, kidneys, liver, endocrine system or immune system may influence how Senozam is metabolized and tolerated.
- Recent infections: Active or recent infections may require treatment or stabilization before an elective infusion.
- Previous reactions to infusions or transfusions: Any past episode of fever, shivering, rash, chest tightness, itching or swelling during an infusion or transfusion should be reported.
- Bleeding disorders or anticoagulant use: These may affect venous access, the risk of haematoma at the infusion site and perioperative planning.
- Planned surgery or invasive procedures: Share your treatment schedule with all treating clinicians so that the timing of Senozam can be coordinated with other interventions.
- Mental health conditions: Anxiety, needle phobia or distress during procedures can often be addressed with appropriate support and should be discussed in advance.
Any intravenous medicine, including Senozam, can in rare cases trigger an acute hypersensitivity or infusion reaction. Warning signs include sudden difficulty breathing, swelling of the face or throat, widespread rash or hives, severe dizziness, loss of consciousness or a rapid drop in blood pressure. If these occur during or shortly after infusion, the infusion will be stopped immediately and emergency treatment initiated. If symptoms appear after you have left the clinic, contact emergency services or your local emergency number without delay.
Tests and Monitoring
Depending on the indication, the prescribing team may request one or more of the following assessments before and during Senozam therapy:
- Baseline blood tests, including full blood count, renal function, liver function and electrolytes.
- Screening for underlying infections relevant to the indication.
- Electrocardiogram (ECG) and/or cardiac imaging, where cardiac safety is relevant.
- Pregnancy testing for patients of childbearing potential, when the SmPC indicates this is necessary.
- Review of concomitant medications for potential interactions.
During infusion, basic vital signs (blood pressure, pulse, respiratory rate and oxygen saturation) are typically monitored according to institutional policy. After the infusion, you may be observed in a recovery area for a specified period before being discharged home.
Pregnancy, Breastfeeding and Fertility
If you are pregnant, think you may be pregnant, are planning a pregnancy or are breastfeeding, tell your doctor before Senozam is administered. Data on the use of Senozam in pregnancy and lactation may be limited; your physician will weigh the potential benefits against the possible risks and consult the current SmPC to determine the most appropriate course of action. In some situations, effective contraception may be required during and for a specified period after treatment.
- A pregnancy test may be performed before treatment begins, particularly for patients of childbearing potential.
- If you become pregnant or suspect you may be pregnant during therapy, contact your doctor without delay.
- Discuss family planning and contraception with your healthcare team before starting and before stopping Senozam.
Driving and Operating Machinery
The effect of Senozam on the ability to drive or operate machinery depends on the dose, the indication and the individual response. Some patients may feel tired, dizzy or light-headed during or after an infusion, especially at the start of therapy. Until you know how Senozam affects you, avoid driving, operating heavy machinery or engaging in activities that require full concentration. Follow any specific advice given by your healthcare team.
Even if you have received Senozam previously, tell the nurse or doctor about any new symptoms, medications, supplements or changes in your health status since your last visit. This ensures that each infusion is prepared and monitored safely.
Children and Adolescents
The use of Senozam in children and adolescents is determined by the authorized indication and the age-specific safety and efficacy data summarized in the SmPC. Paediatric dosing, if permitted, is always based on body weight or body surface area and is calculated individually. Parents and guardians should discuss the risk-benefit balance with the treating paediatrician or specialist.
Older Adults
Older patients may have reduced kidney or liver function, multiple chronic conditions and an increased number of concomitant medications, all of which can influence how Senozam is tolerated. Dose adjustments and more intensive monitoring may therefore be appropriate. Older adults are encouraged to ask their doctor about fall prevention and hydration, particularly if an infusion may cause transient dizziness or changes in blood pressure.
How Does Senozam Interact with Other Drugs?
Senozam can interact with other medicines, herbal products and supplements. Always give your healthcare team a complete list of everything you take, including over-the-counter products. Some combinations may require dose adjustments, extra monitoring or avoidance. The authoritative list of known interactions is in the current Summary of Product Characteristics.
Drug interactions can alter how Senozam works, increase the risk of side effects or affect how another medicine is processed by the body. Because Senozam is administered intravenously, it bypasses first-pass metabolism in the gut and liver, which changes the interaction profile compared with oral medicines. However, shared metabolic pathways, transporter interactions and pharmacodynamic overlap with other agents can still be clinically significant.
Categories of Clinically Relevant Interactions
| Interaction Category | Why It Matters | Action |
|---|---|---|
| Other prescription medicines | Shared metabolic pathways or overlapping side-effect profiles may alter efficacy or safety. | Provide a complete list; your team will check the current SmPC and interaction databases. |
| Over-the-counter (OTC) drugs | NSAIDs, antacids and cold remedies can interact with prescription therapies. | Tell the team about every OTC product you use, including occasional use. |
| Herbal remedies & supplements | Products such as St John's wort, grapefruit-containing supplements or high-dose vitamins can affect drug metabolism. | Disclose all supplements, including those not prescribed or labeled as "natural". |
| Vaccines | Some prescription infusions alter the response to vaccinations or contraindicate live vaccines. | Report recent and planned vaccinations; consult the SmPC before immunization. |
| Alcohol & recreational drugs | Can worsen side effects such as dizziness, sedation, liver stress or bleeding. | Disclose use honestly; discussions are confidential and support better care. |
| Anticoagulants & antiplatelets | May increase bruising, bleeding or complications at the infusion site. | Timing of doses may need to be adjusted; never stop anticoagulants without advice. |
Minor and Pharmacodynamic Interactions
In addition to the categories listed above, minor interactions can occur through shared pharmacodynamic effects. For example, medicines that lower blood pressure, affect heart rhythm or cause drowsiness may have additive effects with other agents you use. Even when an interaction is classified as minor, it can become clinically important in older adults, in patients with multiple conditions or when several interacting medicines are combined. Your clinical team will review your regimen and advise on any monitoring or adjustments required.
Food and Lifestyle Considerations
Because Senozam is given intravenously, there are no specific food restrictions associated with the act of infusion itself; you can usually eat and drink before, during and after treatment, unless advised otherwise for a particular indication. However, general lifestyle recommendations can help the overall treatment plan succeed: maintain good hydration, aim for balanced nutrition, avoid excess alcohol and discuss any significant dietary changes with your healthcare team, particularly if you are on other interacting medicines.
Keep an up-to-date list of all your prescription medicines, OTC drugs, vitamins, herbal products and supplements, including doses and frequencies. Present it at every healthcare visit, especially before an infusion appointment.
What Is the Correct Dosage of Senozam?
The correct dose of Senozam is always determined individually by the prescribing physician based on the indication, the patient's weight and organ function, and the guidance in the Summary of Product Characteristics. Senozam is supplied at 1 mg/ml and infused intravenously under medical supervision. Patients must not adjust the dose or rate themselves.
Because Senozam is a hospital-administered intravenous medicine, the dose is not expressed in the way a patient might be familiar with for tablets or capsules. Instead, the physician calculates the total milligrams required per infusion (often based on weight in mg/kg or body surface area in mg/m²) and the pharmacy or infusion team prepares the correct volume of the 1 mg/ml solution accordingly. The infusion rate is usually expressed in millilitres per hour or milligrams per hour and is controlled by an infusion pump.
Never attempt to change the rate of an infusion yourself. If you feel uncomfortable or experience any new symptoms during the infusion, call the nurse or doctor so that they can assess the situation and respond appropriately.
Adults
Individualized adult dosing
In adults, Senozam is dosed according to the authorized indication, the patient's body weight and clinical parameters. The prescribing team will specify the total dose per infusion, the infusion rate, the frequency of administration and the planned duration of therapy. These decisions are based on the current Summary of Product Characteristics and, where relevant, international and national clinical guidelines.
Children
Paediatric dosing
In paediatric patients, Senozam is only used where it is authorized for the age group concerned. Doses are calculated individually by weight or body surface area and administered under specialist supervision. Parents or guardians should ensure that accurate growth and weight measurements are available at each visit.
Elderly
Older-adult considerations
For older adults, the clinical team may adjust the dose or infusion rate if kidney or liver function is reduced, or if the patient is more sensitive to common side effects such as fluid shifts, dizziness or infusion reactions. A slower infusion rate is sometimes preferred in frail patients.
Patients with Renal or Hepatic Impairment
Organ-impairment considerations
Reduced kidney (renal) or liver (hepatic) function can change how Senozam is cleared from the body. Depending on the indication and the SmPC guidance, this may require dose reduction, extended intervals between infusions or additional monitoring of laboratory parameters before and after each infusion.
Missed Dose
If you miss a scheduled Senozam infusion, contact the clinic or hospital as soon as possible to reschedule. Do not attempt to compensate by requesting a higher dose at the next session; the next infusion will be given at the planned dose, and the overall plan may be adjusted by the prescribing team if necessary.
Overdose
Because Senozam is administered only by healthcare professionals using controlled infusion equipment, accidental overdose by the patient is very unlikely. In the rare event that an excess dose is inadvertently delivered, the infusion will be stopped immediately and supportive treatment initiated. Management of overdose is symptomatic, and there may or may not be a specific antidote; your clinical team will follow the protocol outlined in the SmPC and poisons information services.
Duration of Therapy
The length of a treatment course with Senozam varies widely depending on the indication. Some regimens consist of a single infusion, others involve a fixed number of scheduled infusions, while some require ongoing maintenance therapy. Your doctor will explain the expected duration at the start of treatment and will review it regularly based on response, tolerability and any new clinical developments.
What Are the Side Effects of Senozam?
Like all medicines, Senozam can cause side effects, although not everyone experiences them. The most frequent reactions relate to the infusion process itself (for example fever, chills or headache) and are usually manageable. Serious allergic reactions are rare but require immediate medical care. The complete, indication-specific list of side effects and their frequencies is published in the current Summary of Product Characteristics.
Understanding the range of possible side effects helps patients and caregivers recognize warning signs early and communicate effectively with the healthcare team. The categories below follow the standard international convention for reporting adverse drug reaction frequencies (CIOMS and MedDRA), which is the same framework used in the Summary of Product Characteristics.
Contact your doctor, infusion team or emergency services straight away if you experience any of the following during or after a Senozam infusion: difficulty breathing, swelling of the face, lips, tongue or throat, widespread hives, chest pain, severe dizziness or fainting, high fever with chills, or uncontrolled bleeding. These may be signs of a serious hypersensitivity reaction or other medical emergency.
General Side-Effect Categories
Very Common (may affect more than 1 in 10 people)
- Injection-site reactions: redness, tenderness, swelling or bruising where the cannula was placed
- Headache during or shortly after the infusion
- Fatigue or tiredness, often resolving within a day
- Mild nausea or reduced appetite
Common (may affect up to 1 in 10 people)
- Fever or chills during or after the infusion
- Dizziness on standing or during infusion
- Transient changes in blood pressure or pulse
- Muscle or joint aches
- Gastrointestinal symptoms such as mild stomach discomfort, diarrhoea or constipation
- Skin reactions such as itching or rash
Uncommon (may affect up to 1 in 100 people)
- Moderate infusion reactions requiring the infusion to be slowed or paused
- Changes in laboratory values, such as mild alterations in blood counts or liver tests
- Transient palpitations or feelings of irregular heartbeat
- Visual disturbances such as blurred vision during infusion
- Mood changes such as anxiety around the procedure
Rare (may affect up to 1 in 1,000 people)
- Severe hypersensitivity / anaphylaxis, with swelling, breathing difficulties or shock
- Significant changes in blood cell counts
- Clinically meaningful liver or kidney dysfunction detected on laboratory testing
- Cardiac events, such as chest pain or rhythm disturbances
- Neurological symptoms, such as numbness, tingling or seizures
Infusion Reactions in Detail
Infusion reactions are among the most commonly discussed side effects of intravenous medicines. They typically occur during the infusion itself or within a few hours afterwards and may include flushing, itching, rash, shivering, fever, back pain, shortness of breath or changes in blood pressure. Most infusion reactions are mild to moderate and can be managed by slowing or briefly stopping the infusion, administering supportive treatment (such as antihistamines, antipyretics or corticosteroids) and then resuming carefully. Severe reactions are uncommon but require the infusion to be stopped permanently and full emergency management to be given.
Long-Term and Delayed Effects
Some side effects may appear days or weeks after an infusion, including delayed skin reactions, changes in laboratory values and slower-developing organ effects. For this reason, your clinical team may schedule follow-up blood tests or clinical reviews after each infusion. Report any new symptoms that appear between scheduled visits, even if you are unsure whether they are related to Senozam.
Reporting Side Effects
If you experience any side effect, talk to your doctor, nurse or pharmacist. This also includes any possible side effect not listed in this article or in the package leaflet. You can also report side effects directly to your national pharmacovigilance authority (for example, the MHRA Yellow Card Scheme in the United Kingdom, EudraVigilance in the European Economic Area or MedWatch in the United States). Reporting helps regulators monitor the safety of Senozam in real-world use.
How Should Senozam Be Stored?
Senozam is a hospital-administered infusion product. Storage, preparation and disposal are handled exclusively by pharmacy and clinical staff according to the conditions specified on the product labeling and the Summary of Product Characteristics. Patients do not store Senozam at home.
As a 1 mg/ml solution for infusion, Senozam is supplied in containers (vials, bags or infusion bottles) designed for single-patient use in a clinical environment. The storage conditions — for example, the recommended temperature range, light-protection requirements and shelf life after opening or dilution — are printed on the product labeling and described in the SmPC. Healthcare staff verify these conditions before dispensing and preparing each dose.
Important general principles include the following:
- Do not use the product past the expiry date shown on the label.
- Do not use if the solution appears cloudy, discoloured or contains visible particles.
- Do not use if the packaging is damaged, punctured or shows evidence of tampering.
- Once prepared or diluted, the infusion must be administered within the time window and under the storage conditions specified in the SmPC to maintain sterility and stability.
Unused or partially used product is disposed of according to local pharmaceutical waste regulations. Patients are not required to handle, transport or dispose of Senozam themselves. If you have been given a prescription to take to a hospital or clinic, follow the instructions provided by your pharmacist or prescriber regarding transport to the treatment facility.
Because Senozam is administered on scheduled visits, maintaining an up-to-date appointment card or digital calendar helps ensure that you do not miss an infusion. If your appointment needs to be rescheduled, contact your clinic as early as possible so your treatment plan can be adjusted safely.
What Does Senozam Contain?
The active ingredient in Senozam is senozam, present at a concentration of 1 mg per millilitre of solution for infusion. The formulation also contains excipients that ensure sterility, stability and isotonicity; the exact list is detailed in the official Summary of Product Characteristics and package leaflet.
Active Ingredient
The active substance is senozam. Each millilitre of Senozam solution for infusion contains 1 mg of senozam. The total active ingredient delivered to the patient depends on the prescribed volume and the duration of the infusion.
Excipients (Inactive Ingredients)
Solutions for infusion typically contain a selection of inactive ingredients known as excipients. These may include:
- A suitable solvent (for example, water for injections)
- Agents that adjust tonicity, such as sodium chloride
- Buffering agents to maintain pH within a physiologically appropriate range
- Stabilizers to preserve the active substance during manufacture, storage and administration
The complete, product-specific list of excipients in Senozam is provided in the official Summary of Product Characteristics and the package leaflet that accompanies the medicine. Patients with known excipient sensitivities (for example, to specific buffers, preservatives or solubilizers) should discuss their history with the prescriber before treatment begins.
Appearance and Packaging
Senozam 1 mg/ml solution for infusion is typically presented as a clear, colourless to slightly coloured aqueous solution in sterile containers intended for single-patient use. The product is supplied to hospital pharmacies and clinical units in pack sizes specified on the labeling. Marketing authorization holders may update the packaging and presentation over time in line with regulatory requirements.
Before each infusion, the healthcare team performs independent checks to confirm the product name (Senozam), the strength (1 mg/ml), the batch number and expiry date, and the patient's identity. As a patient, you are encouraged to state your name and date of birth clearly when asked — this is a safety check, not a test.
Frequently Asked Questions About Senozam
Senozam is a prescription-only medicine supplied as a 1 mg/ml solution for infusion. It is administered intravenously by a healthcare professional in a hospital, clinic or other supervised medical setting. Senozam is never self-administered. The specific indication, dose and duration of treatment are determined by the prescribing physician based on the patient's individual condition and the current Summary of Product Characteristics (SmPC).
Senozam must not be given to anyone who is allergic (hypersensitive) to senozam or to any of the excipients in the formulation. Additional contraindications may apply depending on the indication and patient factors such as kidney or liver function, pregnancy or breastfeeding status, age and co-existing conditions. Before treatment, the prescribing doctor reviews the current SmPC and your individual circumstances to confirm that Senozam is appropriate.
As with any intravenous medicine, Senozam can cause infusion-related effects such as fever, chills, headache, nausea, changes in blood pressure or skin rash. Other possible side effects depend on the underlying indication and individual factors. Any new or worsening symptoms during or after an infusion should be reported to the healthcare team so they can be evaluated and managed promptly.
After any intravenous infusion, patients may feel tired, dizzy or unwell for a period of time. Whether it is safe to drive, operate machinery or return to work depends on the indication, the dose received, other medications being used and the individual response. Follow the specific advice given by your treating physician before resuming activities that require full alertness.
Senozam is stored, prepared and handled exclusively by pharmacy and clinical staff at the treatment facility, according to the conditions specified on the product labeling and in the Summary of Product Characteristics. It must not be used after the expiry date. Because Senozam is given as a hospital-administered infusion, patients do not take it home or store it themselves.
Before receiving Senozam, tell your doctor about any allergies, current or past medical conditions, previous reactions to medicines, pregnancy or breastfeeding status, and all medicines you are taking, including herbal products and over-the-counter drugs. This information helps the healthcare team decide whether Senozam is safe for you and whether any precautions, dose adjustments or additional monitoring are needed.
References
- European Medicines Agency (EMA). Guideline on Summary of Product Characteristics (SmPC). Available at: ema.europa.eu. Accessed February 2026.
- U.S. Food and Drug Administration (FDA). Labeling — Prescribing Information Resources. Available at: fda.gov. Accessed February 2026.
- British National Formulary (BNF). Guidance on intravenous infusion therapy and prescription-only medicines. NICE/BNF Publications, current edition.
- World Health Organization (WHO). Model List of Essential Medicines and general principles of safe medication use. Latest edition.
- Council for International Organizations of Medical Sciences (CIOMS). Guidelines for adverse drug reaction reporting and frequency categorization.
- International Council for Harmonisation (ICH). Good Clinical Practice (ICH E6) and Pharmacovigilance (ICH E2) guidelines.
- UK Medicines and Healthcare products Regulatory Agency (MHRA). Yellow Card Scheme — Reporting side effects of medicines. Available at: yellowcard.mhra.gov.uk.
- Institute for Safe Medication Practices (ISMP). Standards for safe intravenous medication administration in acute and ambulatory care.
About the Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialists in clinical pharmacology, hospital medicine, internal medicine and pharmacovigilance. Our content follows the GRADE evidence framework and is based on peer-reviewed research, international clinical guidelines (WHO, EMA, FDA, BNF) and established medical standards.
Every article undergoes a rigorous multi-step review: initial research by medical writers, clinical accuracy verification by specialist physicians, editorial review for clarity and accessibility, and final approval by the Medical Review Board.
We prioritize Level 1A evidence from systematic reviews, randomized controlled trials and regulatory summaries. All medical claims are referenced to authoritative sources. No commercial funding influences our content.
Last medically reviewed: | Published: | Read our editorial standards